Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

J. Thomas, Stephen; Duarte Moreira, Edson; Kitchin, Nicholas; Absalon, Judith; Gurtman, Alejandra; Lockhart, Stephen; L. Perez, John; Pérez Marc, Gonzalo; P. Polack, Fernando; A. F. Zerbini, Cristiano; Bailey, Ruth; A. Swanson, Kena; Xu, Xia; Roychoudhury, Satrajit; Koury, Kenneth; Bouguermouh, Salim; V. Kalina, Warren; Cooper, David; W. Frenck, Robert; L Hammitt, Laura; Türeci, Özlem; Nell, Haylene; Schaefer, Axel; Ünal, Serhat; Yang, Qi; Liberator, Paul; B Tresnan, Dina; Mather, Susan; R. Dormitzer, Philip; Şahin, Uğur; C. Gruber, William; U. Jansen, Kathrin

doi:10.1101/2021.07.28.21261159

Public

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

Published in medRxiv • Jul 28, 2021

Authors:

Stephen J. Thomas

Edson Duarte Moreira

Nicholas Kitchin

Abstract

ABSTRACT Background BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. BNT162b2 is highly efficacious against COVID-19 and is currently authorized for emergency use or conditional appro...

Subject

Medicine

Vaccination

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!